Singapur - inglise - HSA (Health Sciences Authority)

teva pharmaceutical investments singapore pte. ltd. - atorvastatin calcium 41.44 mg corresponding to atorvastatin - tablet, film coated - 40 mg - atorvastatin calcium 41.44 mg corresponding to atorvastatin 40 mg

Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pusat darah negara - albumin human -

Singapur - inglise - HSA (Health Sciences Authority)

goldplus universal pte ltd - atorvastatin calcium trihydrate eqv atorvastatin - tablet, film coated - atorvastatin calcium trihydrate eqv atorvastatin 40.00mg

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

kedrion s.p.a - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin (human) 12.5 g in 50 ml - for restoration and maintenance of circulating blood volume where volume deficiency is demonstrated and colloid use is appropriate. kedbumin® is indicated for severe albumin deficiency caused by illness or active bleeding. when albumin deficiency results from excessive protein loss, the effect of albumin administration will be temporary unless the underlying disorder is reversed. kedbumin® is indicated for maintenance of cardiovascular function following the removal of large volumes of ascitic fluid due to cirrhosis [1, 2]. kedbumin® is indicated as a plasma expander in the fluid management of severe forms of ovarian hyperstimulation syndrome (ohss) [3, 4]. kedbumin® is indicated in conjunction with diuretics to correct fluid volume overload associated with ards [5]. kedbumin® is indicated after > 24 hours post burn in patients experiencing severe albumin depletion in order to favor edema re-absorption [6]. kedbumin® is indicated in patients undergoing long term dialysis or for those patients who are fl

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

kedrion biopharma, inc. - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 10 g in 50 ml - emergency treatment of hypovolemic shock albuked 20 is hyperoncotic and on intravenous infusion will expand the plasma volume by an additional amount, three to four times the volume actually administered, by withdrawing fluid from the interstitial spaces, provided the patient is normally hydrated interstitially or there is interstitial edema.(1) if the patient is dehydrated, additional crystalloids must be given,(4) or alternatively, albumin (human) 5%, usp (albuked™ 5) should be used. the patient’s hemodynamic response should be monitored and the usual precautions against circulatory overload observed. the total dose should not exceed the level of albumin found in the normal individual; i.e., about 2 g per kg body weight in the absence of active bleeding. although albuked 5 is to be preferred for the usual volume deficits, albuked 20 with appropriate crystalloids may offer therapeutic advantages in oncotic deficits or in long-standing shock where treatment has been delayed.(2) removal of ascitic fluid from a

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 5 g in 20 ml - emergency treatment of hypovolemic shock plasbumin-25 is hyperoncotic and on intravenous infusion will expand the plasma volume by an additional amount, three to four times the volume actually administered, by withdrawing fluid from the interstitial spaces, provided the patient is normally hydrated interstitially or there is interstitial edema.(1) if the patient is dehydrated, additional crystalloids must be given,(4) or alternatively, albumin (human) 5%, usp (plasbumin® -5) should be used. the patient’s hemodynamic response should be monitored and the usual precautions against circulatory overload observed. the total dose should not exceed the level of albumin found in the normal individual, i.e., about 2 g per kg body weight in the absence of active bleeding. although plasbumin-5 is to be preferred for the usual volume deficits, plasbumin-25 with appropriate crystalloids may offer therapeutic advantages in oncotic deficits or in long-standing shock where treatment has been delayed.(2) removal of ascitic flu

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 2.5 g in 50 ml - emergency treatment of hypovolemic shock plasbumin-5 is iso-oncotic with normal plasma and on intravenous infusion will expand the circulating blood volume by an amount approximately equal to the volume infused. in conditions associated mainly with a volume deficit, albumin is best administered as a 5% solution (plasbumin-5); but where there is an oncotic deficit, albumin (human) 25%, usp (plasbumin® -25) may be preferred. this is also an important consideration where the treatment of the shock state has been delayed. if plasbumin-25 is used, appropriate additional crystalloid should be administered.(1) crystalloid solutions in volumes several times greater than that of plasbumin-5 may be effective in treating shock in younger individuals who have no preexisting illness at the time of the incident. older patients, especially those with preexisting debilitating conditions, or those in whom the shock is caused by a medical disorder, or where the state of shock has existed for some time before active therapy cou

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

kedrion biopharma, inc. - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 2.5 g in 50 ml - emergency treatment of hypovolemic shock albuked 5 is iso-oncotic with normal plasma and on intravenous infusion will expand the circulating blood volume by an amount approximately equal to the volume infused. in conditions associated mainly with a volume deficit, albumin is best administered as a 5% solution (albuked 5); but where there is an oncotic deficit, albumin (human) 25%, usp (albuked™ 25) may be preferred. this is also an important consideration where the treatment of the shock state has been delayed. if albuked 25 is used, appropriate additional crystalloid should be administered.(1) crystalloid solutions in volumes several times greater than that of albuked 5 may be effective in treating shock in younger individuals who have no preexisting illness at the time of the incident. older patients, especially those with preexisting debilitating conditions, or those in whom the shock is caused by a medical disorder, or where the state of shock has existed for some time before active therapy could be insti

Belgia - inglise - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

centrale afdeling voor fractionering - departement central de fractionnement s.p.r.l.-b.v.b.a. - albumin human 200 mg/ml - solution for infusion - 20 % - albumin human 200 mg/ml - albumin

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

bpl - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albuminex 25% is indicated for restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate e.g. hypovolemia following shock due to trauma or sepsis, in surgical patients and in other similar conditions with volume deficiency when restoration and maintenance of circulating blood volume is required in both adult and pediatric patients. in pediatric patients to reverse hypovolemia and achieve normal capillary refill time. 1, 2, 3, 4, 5, 6, 7, 8 albuminex 25% is indicated for prevention of central volume depletion and maintenance of cardiovascular function after large volume parencentesis in patients with liver cirrhosis or other chronic liver disease in adults and children. 9, 10, 11, 12 albuminex 25% infusion plus administration of vasoactive drugs is indicated in the treatment of type i hepatorenal syndrome. 6 for patients with spontaneous bacterial peritonitis, albuminex 25% is indicated as adjuvant treatment to antibiotic therapy.